COVID-19 in gastroenterology: Where are we now? Current evidence on the impact of COVID-19 in gastroenterology

United European Gastroenterol J. 2021 Sep;9(7):750-765. doi: 10.1002/ueg2.12115. Epub 2021 Jun 30.

Abstract

Background: The COVID-19 pandemic has created unprecedented challenges in all fields of society with social, economic, and health-related consequences worldwide. In this context, gastroenterology patients and healthcare systems and professionals have seen their routines changed and were forced to adapt, adopting measures to minimize the risk of infection while guaranteeing continuous medical care to chronic patients.

Objective: At this point, it is important to evaluate the impact of the pandemic on this field to further improve the quality of the services provided in this context.

Methods/results/conclusion: We performed a literature review that summarizes the main aspects to consider in gastroenterology, during the pandemic crisis, and includes a deep discussion on the main changes affecting gastroenterology patients and healthcare systems, anticipating the pandemic recovery scenario with future practices and policies.

Keywords: COVID-19; SARS-CoV-2; endoscopy; gastroenterology; inflammatory bowel disease; vaccination.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Biomarkers
  • COVID-19 / complications
  • COVID-19 / immunology
  • COVID-19 / physiopathology*
  • Delivery of Health Care*
  • Disease Management
  • Endoscopy, Digestive System
  • Gastroenterology*
  • Gastrointestinal Diseases / etiology
  • Gastrointestinal Diseases / physiopathology
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Inflammatory Bowel Diseases / drug therapy*
  • Inflammatory Bowel Diseases / immunology
  • Inflammatory Bowel Diseases / metabolism
  • Liver Diseases / complications
  • Liver Diseases / physiopathology*
  • Liver Diseases / surgery
  • Liver Transplantation
  • Pancreas / metabolism
  • Pancreas / physiopathology
  • Risk Factors
  • SARS-CoV-2
  • Telemedicine

Substances

  • Biomarkers
  • Immunosuppressive Agents